Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 61% Improvement Relative Risk c19hcq.org Satti et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 80 patients in Qatar Fewer cases with HCQ (p=0.041) Satti et al., Cureus, doi:10.7759/cureus.24382 Favors HCQ Favors control
Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar
Satti et al., Cureus, doi:10.7759/cureus.24382
Satti et al., Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic.., Cureus, doi:10.7759/cureus.24382
Apr 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 80 consecutive pregnant patients with autoimmune rheumatic diseases in Qatar, showing lower risk of COVID-19 cases with HCQ prophylaxis. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of case, 61.5% lower, RR 0.39, p = 0.04, treatment 10 of 63 (15.9%), control 7 of 17 (41.2%), NNT 4.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Satti et al., 22 Apr 2022, retrospective, Qatar, peer-reviewed, 6 authors.
Contact: salemadi@hamad.qa.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Open Access Original Article DOI: 10.7759/cureus.24382 Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar Review began 04/11/2022 Review ended 04/21/2022 Eman Satti 1 , Monika Ostensen 2 , soha darrgham 3 , Nawal Hadwan 4 , Hadeel Ashour 4 , Samar AL Emadi 4 Published 04/22/2022 © Copyright 2022 Satti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., 1. Intenal Medicine, Rheumatology Section, Hamad Medical Corporation, Doha, QAT 2. Department of Rheumatology, Sorlandet Hospital, Kristiansand, NOR 3. Biostatistics, Epidemiology, and Biomathematics Research Core, Weill Cornell Medicine, Doha, QAT 4. Internal Medicine, Rheumatology Section, Hamad Medical Corporation, Doha, QAT which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Corresponding author: Samar AL Emadi, salemadi@hamad.qa Abstract Objective: Pregnant women with autoimmune rheumatic diseases are considered to have a high risk of obstetric complications with the emergence of the Coronavirus disease (COVID-19) pandemic. Therefore, we aimed to assess the impact of COVID-19 on this high-risk group. Methods: This cross-sectional cohort study (March to December 2020) was conducted at the largest tertiary center in Qatar (Hamad Medical Corporation). Eighty consecutive patients following up at the center during pregnancy were surveyed through telephonic interviews. Data on COVID-19 and pregnancy outcomes were extracted from electronic hospital records. Results: Eighty pregnant women with autoimmune rheumatic diseases were included. Among them, 17 (21.3%) (95% confidence interval [CI]: 12.9-31.8%) were diagnosed with COVID-19, five were hospitalized, and only one required intensive care unit admission. The proportion of adverse obstetric outcomes in the cohort was 29.5% (n = 23; 95% CI: 19.7-40.9%). Prematurity (n = 14; 19.4%) and caesarean section (n = 30; 41.1%) were the most prevalent adverse events. There was no statistical difference in adverse pregnancy outcomes between women with and without COVID-19. Conclusion: COVID-19 did not affect pregnancy outcomes in women with autoimmune rheumatic diseases. Categories: Obstetrics/Gynecology, Infectious Disease, Rheumatology Keywords: autoimmune rheumatic diseases, caesarean, covid-19, prematurity, pregnancy
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit